Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongming Qu

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Diabetes Care|June 27, 2013
Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147Richard M Bergenstal, Julio Rosenstock, Richard F Arakaki, et al.
Diabetes Care|July 13, 2012
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetesRichard M Bergenstal, Julio Rosenstock, Richard F Arakaki, et al.
Biometrical Journal. Biometrische Zeitschrift|September 22, 2023
CITIES: Clinical trials with intercurrent events simulatorAhmad Hakeem Abdul Wahab, Yongming Qu, Hege Michiels, et al.
Diabetes Care|November 30, 2012
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover studyJulio Rosenstock, Richard M Bergenstal, Thomas C Blevins, et al.
Obesity Science & Practice|December 30, 2025
Relationships Between Metabolic and Bariatric Surgery and Adverse Kidney Outcomes: An Analysis of a Retrospective CohortKevin C Maki, Stephanie L Dickinson, Carol F Kirkpatrick, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 2, 2005
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) studyEthel S Siris, Steven T Harris, Richard Eastell, et al.
Bone|December 22, 2006
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone massRobert R Recker, David Kendler, Christopher P Recknor, et al.
Diabetologia|July 22, 2024
Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trialsJoseph Mellor, Dmitry Kuznetsov, Simon Heller, et al.
Diabetologia|May 25, 2024
Risk factors and prediction of hypoglycaemia using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trialsJoseph Mellor, Dmitry Kuznetsov, Simon Heller, et al.
Diabetes Care|April 6, 2026
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDNaveed Sattar, Hertzel C Gerstein, David D'Alessio, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Diabetes Care|June 27, 2013
Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147Richard M Bergenstal, Julio Rosenstock, Richard F Arakaki, et al.
Diabetes Care|July 13, 2012
A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetesRichard M Bergenstal, Julio Rosenstock, Richard F Arakaki, et al.
Biometrical Journal. Biometrische Zeitschrift|September 22, 2023
CITIES: Clinical trials with intercurrent events simulatorAhmad Hakeem Abdul Wahab, Yongming Qu, Hege Michiels, et al.
Diabetes Care|November 30, 2012
Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover studyJulio Rosenstock, Richard M Bergenstal, Thomas C Blevins, et al.
Obesity Science & Practice|December 30, 2025
Relationships Between Metabolic and Bariatric Surgery and Adverse Kidney Outcomes: An Analysis of a Retrospective CohortKevin C Maki, Stephanie L Dickinson, Carol F Kirkpatrick, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 2, 2005
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) studyEthel S Siris, Steven T Harris, Richard Eastell, et al.
Bone|December 22, 2006
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone massRobert R Recker, David Kendler, Christopher P Recknor, et al.
Diabetologia|July 22, 2024
Estimating risk of consequences following hypoglycaemia exposure using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trialsJoseph Mellor, Dmitry Kuznetsov, Simon Heller, et al.
Diabetologia|May 25, 2024
Risk factors and prediction of hypoglycaemia using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trialsJoseph Mellor, Dmitry Kuznetsov, Simon Heller, et al.
Diabetes Care|April 6, 2026
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDNaveed Sattar, Hertzel C Gerstein, David D'Alessio, et al.
Pageof 8